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Benzimidazoles: From 
Antiproliferative to Multitargeted 
Anticancer Agents
Yousef Najajreh
Abstract
Benzimidazole derivatives are known to act against a range of biological targets 
and thus gained clinical applications in a wide spectrum of diseases. Few examples 
of multitargeted benzimidazole derivatives that were reported during the last decade 
will be described in this chapter. Multitargeting agents for serving the polyphar-
macology approach to combat shortcomings of the main one-drug-one target main 
dogma will be briefly explored. In that context, the multitargeting benzimidazole 
derivatives gain a special attention. This includes discovery (hit-to-lead), structure-
activity relationship (SAR), and binding mode of at least one lead (or hit) in each 
group. Special attention will be given to two structures dovitinib and AT9283 that are 
reported to exhibit potent in vitro and in vivo activities against a group of kinases and 
non-kinase target (as shown recently for dovitinib).
Keywords: benzimidazole, selective, cytotoxic, inhibitor, multitargeting, 
multikinase, polypharmacology, antiproliferative, quinolinone, carbamate, 
quinolinone, pyrazole, urea, aniline, anilinobenzimidazolylpyrimidine, 
chloroacetamide, amidine, binding, mode
1. Introduction
1.1 Antiproliferative action of benzimidazoles
Benzimidazole, a heterocyclic moiety comprising six-membered benzene ring 
fused with five-membered imidazole ring, containing molecules, was known for its 
ability to induce antiproliferative effects (named as antineoplastic, anticancer, or 
antitumor agents). Numerous structures were reported as effective inhibitors of cell 
growth and division, thus acting as antiviral, antibacterial, antifungal, anthelmintic 
(or antihelminthics), and anticancer agents. Over the years, several published 
scripts have reviewed the synthetic approaches, medicinal chemistry, SAR, bioac-
tivities, and preclinical and clinical studies of such “gifted” fragment [1–8].
1.2 Benzimidazoles act on numerous biological targets
A wide range of activities and medical situations benzimidazole containing 
compounds have been used for. That includes antihypertensive [9–12], anti-inflam-
matory [13–15], antibacterial [16–18], antiviral [19–21], antifungal [22–24], anti-
helmintic [25–28], anticancer [29–32], antiulcer [33–35], antioxidant [36–38], and 
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psychoactive drugs [39]. And proton pump inhibitors [8, 33], anticoagulants [40, 
41], immunomodulators [42], hormone modulators [43, 44], antidepressants [45], 
lipid level modulators [46–49], and antidiabetics [50–52] are partial list of thera-
peutic effects of benzimidazole containing comprising compounds. Benzimidazole 
derivatives exert their actions by interacting with vital biological targets including 
β-tubulin [52–55], DNA minor groove [56–58], serotonin receptors (5-hydroxy-
tryptamine receptors; 5-HT) [59–62], histamine receptors 4 (H4H) [63], dopamine 
receptor 2 (D2R) [64], chemokine receptor (CXCR3) [65], interleukin 2-inducible 
T-cell kinase (ITK) [66], lymphocyte tyrosine kinase (Lck) [67], phosphatidylino-
sitol 3-kinase (PI3K) [68], activated protein kinase (MEK1) [69, 70], anaplastic 
lymphoma kinase (ALK) [71], polo-like kinase 1 (PLK1) [72, 73], breakpoint cluster 
region-Abelson kinase (BCR-Abl) [74], casein kinase 2 (CK2) [75], telangiectasia 
and Rad3-related protein kinase (ATR) [76], tyrosine kinase receptors [fibroblast 
growth factor receptors (FGFR-1/FGFR-2/FGFR-3)], vascular endothelial growth 
factor receptor (VEGFR-1/VEGFR-2/VEGFR-3), platelet-derived growth fac-
tor receptor (PDGFR-α/PDGFR-β), stem cell factor receptor (c-KIT), FMS-like 
tyrosine kinase 3 (FLT3) [77], poly(ADP-ribose)polymerase-1 (PARP-1) [78–82], 
dihydroorotate dehydrogenase (DHODH) [83], topoisomerase 1 (TOPO1) [84], 
DNA and RNA polymerases [85–89], histone deacetylase 2 (HDAC2) and sirtuin 
[3, 90], antagonism of angiotensin 1 [2], neuropeptide Y binding [91], inhibition of 
proton pumps [8], DNA intercalating agents [92], inhibition of cyclin-dependent 
kinases (CDK) activity [93–96], activation of the p53 protein [97], etc. to mention 
part of the asserted cellular targets.
1.3 Scope: benzimidazoles as emerging multitargeting agents
The profound success in bringing into clinical application several kinase inhibi-
tors as anticancer drugs made “kinase targeting” a central branch of targetable 
biomolecules during the past two decades. Nevertheless, the emerging of resistant 
tumors kinase-directed therapeutics and adverse side effects turned such promising 
“targeted therapeutics” into challenging field. In addition, it was noticed that lack 
of response to kinase inhibitors is accompanied by changes in signaling network 
composition through adaptive kinome reprogramming. Such reprogramming is 
believed to allow the tumor to escape effects of the drug and manifest resistance. 
In contrast to the “one-drug-one-target” approach, the “bitopic, that is, two drugs 
acting on one target” or the “dual, that is, one drug acting on two targets,” “poly-
pharmacology” which refers to a novel paradigm that purposes at “simultaneous 
modulation of more than two biological targets by a single drug” has been emerging 
as strategy to improve the efficacy and durability of clinical responses to therapies. 
In cancer treatment, polypharmacology is a result of the ability of “one drug” to 
simultaneously inhibit multiple cancer-driving targets. However, discovering 
inhibitors with an appropriate multitarget profile is a challenging task that neces-
sitates a systemic deeper investigation accompanied by major clinical developments. 
Therefore, a strategy is required to identify single polypharmacological agents with 
the ability to target multiple cancer-promoting or -sustaining pathways that does 
not necessarily rely on inhibiting multiple kinases [98]. As a matter of fact, high 
ratio (~30%) of the FDA-approved kinome-targeting drugs were reported be mul-
titargeted ones [99]. Actually, the first kinase inhibitor imatinib was approved as 
multitarget agent in a later stage (in addition to its primary target BCR-Abl, it inhib-
its stem cell factor receptor (c-KIT) and platelet-derived growth factor receptors 
A and B (PDGFRα and PDGFRβ) tyrosine kinases and human quinone reductase 2 
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Figure 1. 
Multitargeting anticancer agents. (a) Multitargeting cytotoxic benzimidazole-based structures. 
3-Benzimidazol-2-ylhydroquinolin-2-one based dovitinib [TKI258, CHIR258; (1)], N-cyclopropyl-
N’-[3-[5-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]Urea [AT9283 (2)], 
2-anilino-4-(benzimidazol-2-yl)pyrimidine based [2-anilino-4-(benzimidazol-2-yl)-pyrimidine 2-methoxy-
5-{[4-(1-methyl-1H-benzimidazol-2-yl)pyrimidin-2-yl]amino}phenol (3)], α-haloacetamidebenzimidazole-
based [2-chloro-N-(2-(p-tolyl)-1H-benzo[d]imidazol-5-yl)acetamide (4)], and amidine-benzimidazole based 
[2-(4-((1-benzyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-5-(4,5-dihydro-1H-imidazol-2-yl)-1H-benzo[d]
imidazole (5)]; (b) FDA-approved multitargeting anticancer agents [sorafenib (6), regorafenib (7) sunitinib 
(8), axitinib (9), and lenvatinib (10) and pazopanib (11)].
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(NQO2)). Thus the question of how efficacious are selective and specific one-drug-
one-target-approved agents in treating advanced and metastatic cancer is still under 
evaluation [100–102].
This chapter will concisely provide a deeper insight into the benzimidazole-
containing structures that exhibit action on multiple cellular targets. Special focus 
will be drawn to the identification and discovery, the structural activity relation-
ship, proposed binding and interaction, and mechanism of action of each group of 
compounds. Detailed synthetic procedures and preclinical and clinical studies are 
out of scope of the current chapter. The focus of this chapter will be on groups of 
compounds that had been unveiled as concurrently antagonizing multiple targets. 
Instead, this chapter will focus on five groups of compounds reported to possess 
cytotoxic activities by acting on multiple (see Figure 1a) compounds (1, 2, 3, 4,  
and 5) holding the potential to be administered as “polytherapies.”
2. Benzimidazole scaffold for multitargeting of cancer
Multitargeting agent is defined as “a single chemical entity exerting action as a 
result of direct interactions on multiple biomolecular targets” [103]. Such agents 
can be beneficial in overcoming single (or dual)-targeting limitations including 
compromised effectiveness, severe side effects, emergence of resistant target 
mutants, and target non-related mutations. In addition, the efficacy of single-
molecular-targeted FDA-approved agents in treating brutal and mortal cancers 
(breast, colorectal lung, pancreatic, and prostate) is limited. Most tumors escape 
from the inhibition of any single chemotherapeutic agent, and thus one possible 
therapeutic strategy could be in (1) administering cocktails of highly selective 
inhibitors (combinational therapy) or (2) development of multitarget inhibitors 
that act on inhibiting concurrently multiple validated target in cancer cell initiating 
a concerted molecular response, leading to cell death. Multitargeting chemothera-
peutics hold the potential of exhibiting synergistic or at least additive effects when 
compared to single-targeted ones. It is believed that advances in signaling cascades, 
networks and crosstalk, chemo- and bioinformatics, detailed three-dimensional 
structural information of target proteins, computational chemistry tools, pro-
teomics, etc. will allow for designing novel multitarget inhibitors.
It has been realized that molecular targeted therapeutics are facing acquired 
resistance. Multitargeting approach is gaining increased attention especially when 
combating resistant cancer cells. Accumulated evidence showed that drug treat-
ment aggravates “selective pressure” of evolutionary force exerted on tumor cells 
that leads to resistance.
Benzimidazole fragment is reported to be an integral part of multitargeted 
inhibitors. Such inhibitors challenge the dominant paradigm in drug discovery 
which deemed to design and develop bioactive agent with maximum selectivity 
and specificity to individual drug target. Such compounds hold the hope for a new 
avenue of combating disease cases that could not be cured with one inhibitor acting 
on single target such as cancer [104, 105].
2.1 Benzimidazolylquinolinone: a scaffold for targeting multiple biomolecules
2.1.1 Discovery of dovitinib (TKI258, CHIR258)
Dovitinib [(TKI258, CHIR258); 4-amino-5-fluoro-3-(5-(4-methylpiperazin-
1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one (1)] was first designed and 
synthesized as vascular endothelial growth factor receptor (FEGFR) inhibitor in the 
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context of developing targeted antiangiogenic treatments [106]. The compound was 
later reported as a multitargeted kinase inhibitor (by [107]) following the realization 
that its potent inhibitory effects on cancer cells are associated with action on other 
multiple key players in oncogenesis, development, and proliferation of cancer [107].
The commercially available 3-benzimidazol-2-ylhydroquinolin-2-one scaffold 
[benzimidazolylquinolinone for short from now on, Figure 2 (13)] was identi-
fied using high-throughput screening (HTS) method and reported by Renhowe 
et al. (Novartis) as a potent (IC50 values < 0.1 μM) reversible ATP competitive 
inhibitor of VEGFR-2, FGFR-1, and PDGFRβ [106]. Due to desirable properties 
as low-molecular-weight compound exhibiting submicromolar activity, (12) was 
considered a good hit to start with. To overcome the undesirable physicochemical 
properties of (13) (low aqueous solubility), further optimization was needed that 
ended up with a drug-like compound (1). Determining the key structural features 
required for potent kinase inhibition, molecular modeling was employed. The 
assumption was that in quinolinone portion, both NH at position 1 and the carbonyl 
group, together with benzimidazole NH, form a donor-acceptor-donor motif that 
would most probably bind to the hinge region of the RTKs and should be preserved.
To test this hypothesis, a systematic study was conducted through which 
hydrogen bond donors were masked by methyl group (CH3-) as shown in Figure 3 
(13a–c) and 14a and 14b. These changes led to significant loss in the potency against 
all three receptor tyrosine kinases (VEGFR-2, FGFR-1, and PDGFRβ RTKs). The 
dimethylated analogue (Figure 3, 14b) showed no kinase activity at a concentration as 
high as 25 μM. Interestingly, it was noticed that monomethylation seemed to affect 
the kinase selectivity profile as well. Introduction of a methyl on the benzimidazole 
NH (13b) had a more dramatic effect on VEGFR-2 affinity than the methylation at 
NH in position 1 of the hydroquinolin-2-one (13a). This underlies the importance 
Figure 2. 
Benzimidazolquinolinone-based multitargeting scaffold. (a) The basic skeleton of dovitinib (TKI258, 
CHIR258), 3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one (12) with the two fragments quinolinone (blue) and 
benzimidazole (red) is indicated, (b) structures of commercially available starting “hit” (13) identified using 
HTS, and the “lead” approved as a multitargeting drug dovitinib (1).
Figure 3. 
Assessing the effect of the HBD and HBA on the activity of derivative of 3-benzimidazol-2-ylhydroquinolin-
2-one. Methylated analogues of (13 and 14). The monomethylation caused a significant drop in the potency 
toward RTKs, while dimethylation aborted the RTKs’ activity [106].
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of preventing the hydrogen bond donor (HBD). An opposite effect was noticed for 
FGFR-1, which indicates that despite the high homology of the two ATP-binding 
sites in the tow targets, selectivity opportunities still exist that are likely due to 
small changes in the shape of binding site. Such change in the shape can influence 
the accessibility of alternate binding poses of the monomethylated ligands (13a–13b 
and 14a in Figure 1) [106].
2.1.1.1 Structure–activity relationship (SAR)
The scaffold (13) was annotated by four rings (A–D). Modifications were 
introduced in a systemic manner. Once the basic structural components needed for 
affinity to targets of interest were understood, a study of the structure–activity rela-
tionship around the periphery of central 3-benzimidazol-2-ylhydroquinolin-2-one 
(13) scaffold was undertaken. Besides electrophilicity, nucleophilicity, bulkiness, 
steric hindrance, HBD versus HBA, and basicity, C4 of ring A was used for incorpo-
ration of moieties that might impart favorable physicochemical properties.
SAR of ring B (C4): While removal of the hydroxyl group reduced the activity, 
its replacement with amine improved significantly affinity to RTK and also cell 
potency [EC50 of 0.078 μM (NH2 > OH > H)], suggesting an importance of the 
HBD at C4 of the hydroquinolin-2-one fragment. Thus, incorporation of larger 
substituents on the C4-NH of the hydroquinolin-2-one was explored and found to 
be tolerated (see compounds 15b and 15c, Figure 4). Not only substantial improve-
ment in the solubility was attained when the substituents carried an additional 
basic nitrogen were introduced to this position, it was noticed that this position 
modulates the selectivity profile of this class of compounds. It was reported that 
both derivatives (12a) and (12b) exhibited enhanced potency against PDGFR than 
VEGFR-1 (3000-fold) and FGFR (>1500-fold). Large basic amines like aminoqui-
nuclidine potentiate the derivative (15d) against CHK-1 and GSK-3.
Figure 4. 
Summary of structure–activity relationship (SAR) of 3-benzimidazol-2-ylhydroquinolin-2-one (1) [106].
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In conclusion, substitution at C4 position was revealed as critical to the activ-
ity of the benzimidazolylhydroquinolinone scaffold; however for RTK inhibitor 
program, the NH2 group was the optimal substituent at C4 as it avoided inhibition 
of these additional serine threonine kinases, which could complicate the pharmaco-
logical application of these agents.
SAR of ring D: The overall structure–activity relationship (SAR) is summarized 
in Figure 4. Medicinal chemistry efforts were concluded in the selection of com-
pound (1) as a candidate for further development. The compound (1) displayed 
exceedingly potent inhibitory effect when assessed against receptor protein kinases 
VEGFR-2, FGFR-1 and FGFR-3, PDGFRβ, VEGFR-1, VEGFR-2 and VEGFR-3, 
c-KIT, CSF-1R, and FLT-3 with IC50 values between 3 and 27 nM. Such activity is 
translated into antiproliferative action on cells that are VEGF-, FGF-, SCF-, CSF-, 
or PDGF-driven. Mechanistically, it was also indicated that VEGF-mediated ERK 
phosphorylation was dipped in endothelial cells treated with (1).
In summary, dovitinib (1), an antineoplastic benzimidazolylquinolinone 
derivative, inhibits multiple growth factor receptor tyrosine kinases important for 
tumor angiogenesis and tumor growth. Dovitinib is well established as type III–V 
receptor tyrosine kinase (RTK) inhibitor. Though it potently inhibits fibroblast 
growth factor receptors (FGFR-1/FGFR-2/FGFR-3), the compound also inhibits 
vascular endothelial growth factor receptor (VEGFR-1/VEGFR-2/VEGFR-3), 
platelet-derived growth factor receptor (PDGFR-α/β), stem cell factor receptor 
(c-KIT), FMS-like tyrosine kinase 3 (FLT3), and colony-stimulating factor recep-
tor 1 (CSFR-1) emphasizing the nonspecific action of the drug [108]. The orally 
bioavailable lactate salt of (1) strongly binds to fibroblast growth factor receptor 
3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of 
tumor cell proliferation and the induction of tumor cell death. The activation of the 
abovementioned RTK in singularity or together is associated with cell proliferation 
and survival in all cancer cell types.
Dovitinib (TKI258, 1) is a highly potent, novel multitargeting receptor tyrosine 
kinase inhibitor with IC50 of 1, 2, 10, 8, 27, and 36 nM for FLT3, c-KIT, VEGFR-1/
VEGFR-2/VEGFR-3, PDGFRß, and CSFR −1, respectively. Due to its inhibitory 
effect of VEGFR1/VEGFR2, the compound displayed both antitumor and antian-
giogenic activities in vivo.
Trudel and colleagues reported that in addition to inhibiting the abovemen-
tioned TRKs (types II, IV, V), (1) potently inhibits wild-type (WT) FGFR3, 
F384 L-FGFR3 (IC50 = 25 nM), and FGFR3 mutants (IC50 = 70–90 nM for the 
various mutations) driven by B9 cells [107]. Additionally, same group reported 
that (1) inhibited the proliferation of multiple myeloma (MM) cells. When assess-
ing its antiproliferative effect against U266 and 8226 cells, (1) displayed a potent 
inhibitory effect (IC50 ~ 90 nM) against KMS11 (FGFR3-Y373C), OPM2 (FGFR3-
K650E) cells and IC50 ~ 550 nM KMS18 (FGFR3-G384D) [109]. (1) Exhibited 
exceedingly potent antiproliferative effect against acute myelogenous leukemia 
(AML) cells MV4;11 (mutant FLT3-ITD) compared to AML RS4;11(FLT3 WT) cells 
[EC50 = 13 nmol/L and EC50 = 315 nmol/L for MV4;11 and RS4;11, respectively, i.e., 
(~24-fold decrease in potency for FLT3 WT cells)]. Such results indicated that (1) 
exhibited far more potent activity against cells that are dependent on constitutively 
active FLT3-ITD. A similar conclusion was affirmed by Heise et al. by the notion 
that (CHIR258, 1) inhibited the proliferation of MOLM13 and MOLM14 that are 
FLT3-ITD mutant cells with EC50 ∼ 6 nmol/L similar to the ones with MV4;11 [109].
Besides the potent action of (1) against a wide range of RTK, its inhibitors’ effect 
ion fibroblast growth factor receptors in a variety of tumor xenograft models in 
athymic mice, including acute myeloid leukemia, multiple myeloma, and colon- 
and prostate-derived models was promising.
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Recent studies reported the comparative activities of dovitinib against 16 
colorectal cancer (CRC) cell lines (among them, 10 were KRAS or BRAF mutants). 
Results showed the affectivity of the drug in inhibiting the proliferation of majority 
of the cell lines excluding the ones harboring KRAS or BRAF mutants. However, 
when assessing the efficacy of the drug in vivo, it reduced the tumor growth in vivo 
regardless of the KRAS and BRAF mutation status. The drug exerted significant 
reduction of the xenograft size of both resistant cell lines (KRAS mutant LoVo cells 
but not in BRAF mutant HT-29) but without a detectable effect in the resistant 
mutant cell BRAF mutant HT-29 in vitro on s. Such results were explained by the 
multitarget action of the drug in which by acting on FGFR and FGFR together with 
VEGFR has been able to interfere with resistance mechanisms emerging from the 
synergistic interaction between the various signaling cascades in promoting neo-
vascularization that is believed to be one resistance factor in renal cell carcinoma or 
pancreatic cancer [110, 111].
Dovitinib was selected to proceed ahead for preclinical and clinical trials. 
Several clinical trials have been conducted, and others are also underway with 
the drug and alone or in combination with several chemotherapeutic agents 
[112–118].
2.1.2 Binding mode of dovitinib (CHIR258, 1) to FGFR-1
Based on FGFR-1 crystal structure (PDB 2FGI) in conjunction with the informa-
tion received from the X-ray structure of (1) with CHK1, a homology model for (1) 
complexed with VEGRF2 was constructed [106]. The model was helpful in guid-
ing for the important interactions of (1) with active site. It was concluded that (1) 
participated in three hydrogen bonds to the hinge domain (Glu917 and Cys919). In 
addition A-ring makes a VDW interaction with the hydrophobic gatekeeper Val916 
and was engaged in an S-H/π interaction with Cys1045. Leu840, Val848 (both in the 
P-loop and ceiling of the purine pocket), Ala866 (ceiling of the purine pocket), Val 
899 (floor of the purine pocket), Phe918 (part of the hinge), Lys920, Gly922 (both 
in the lower hinge region), and Leu1035 (floor of the purine pocket) took part in 
hydrophobic interaction with (1). In the following studies, the X-ray structures of 
(1) complexed with native and with mutant FGFR1 and with FGFR4 were reported 
[119–122].
2.1.2.1 Going beyond kinases
Although dovitinib binds to several kinases at nanomolar concentrations, 
recent studies reported its inhibitory effect against cancer-related targets including 
topoisomerase I and II (Topo I and II) [123] and human recombinant bone morpho-
genetic protein (BMP)-2, indicating that the cell growth inhibitory activity and the 
anticancer activity of dovitinib may result, in part, from its ability to target Topo I 
and II in addition to the ability to inhibit multiple kinases [124]. A study disclosed 
dovitinib inhibition of BMP-2 enhanced alkaline phosphatase (ALP) induction, 
which is a representative marker of osteoblast differentiation. Dovitinib also stimu-
lated the translocation of phosphorylated Smad1/Smad5/Smad8 into the nucleus 
and phosphorylation of mitogen-activated protein kinases, including extracellular 
signal-regulated protein kinases 1 and 2 (ERK1/2) and p38 Figure 5. An increase 
in the expression of mRNA of BMP-4, BMP-7, ALP, and osteocalcin (OCN) was 
noticed following treatment with (1). It was also noted that the potent stimulating 
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effect of (1) on BMP-2-induced osteoblast differentiation suggests a potential 
repositioning for the use of (1) treatment of bone-related disorders [124]. In a 
recent study, Ye Zhang et al. initially used the central scaffold 3-(1H-benzimidazol-
2-yl)quinolin-2(1H)-one (12) to explore that potential diversification of functional 
groups decorating (12). The compounds synthesized were assessed against HepG2 
(human liver cancer cells), SK-OV-3 (human ovarian cancer cells), NCI-H460 
(human large cell lung cancer cells), BEL-7404 (human liver cancer cells), and 
HL-7702 (human liver normal cells) cell lines. Initial studies showed that halo-
genated derivative [3-(6-chloro-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 
(15e) and 3-(6-bromo-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one (15f) (see 
Figure 4)] exhibited better activity than 5-FU and cisplatin when assessed against 
HepG2, SKOV-3, NCI-H460, and BEL-7404 but not HL-7702. The authors postu-
lated that (15e) and (15f) inhibit HepG2 proliferation by blocking the cells in G2/M 
stage through activation of p53 protein.
Figure 5. 
(a) Cartoon representation of the crystallographic structure of complex of (1) to FGFR-1 (PDB 5 AM6); the 
binding site is depicted showing the kinase with residues interacting with the ligand in stick model, (b left) the 
main interactions between (1) and the kinase domain and (b right) the surface representation, with the surface 
colored by atom type (red, oxygen; blue, nitrogen; yellow, sulfur; gray, carbon/hydrogen). The donor-acceptor-
donor motif is shown to interact with the hinge region while the 1-methylpiperazine substituent on C5′ points 
into solution [119].
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2.2 Pyrazolbenzimidazols as multikinase inhibitors
2.2.1 Discovery of AT9283a
In developing a selective potent aurora kinase inhibitor by employing fragment-
based discovery method, the pyrazol-4-yl urea benzimidazole derivative (AT9283, 
21) was identified as a multitargeting kinase inhibitor. The pyrazolebenzimidazole-
based clinical candidate (21) was optimized by Steven Howard and his colleagues 
following efficient structure-guided fragment to hit IC50 as low as 3 nM activity 
as a dual potent inhibitor toward Aurora A/Aurora B [125]. AT9283 was identified 
starting from the pyrazole-benzimidazole fragment (16) that was previously identi-
fied during the endeavor of developing cyclin-dependent kinase (CDK) inhibitors. 
Subsequent structure-based approach using CDK2 crystallographic structure led to 
the identification of the benzamide analogue (18). Throughout the process of devel-
oping CDK2 inhibitors, pyrazole-benzimidazole derivative was identified to act with 
high potency toward Aurora A. Starting with fragment, (18) demonstrated superior 
ligand efficiency (LE = 0.59) for Aurora A compared to CDK1 and CDK2 and also 
sufficient potency to allow detection in a conventional enzyme bioassay [125].
Aiming at optimizing, the “hit” (18) on the way to end up with a lead SAR is per-
formed on the benzamide analogues. The team was aided by polyploid phenotype in 
HCT116 cells, as a functional assay that differentiates for Aurora A and Aurora B inhi-
bition, combined with potency when screening for further analogues. Guided by the 
hypothesis that introducing a basic motif into fragment (18) will improve the potency 
of the compound, modifications were introduced successfully to 5- or 6- position of 
the benzimidazole without causing any clashes with the protein. In a further step, the 
morpholinomethyl motif was functionalized at position 5. Details grasped from the 
X-ray crystal structure of (19) complexed with Aurora A revealed that the pyrazole-
benzimidazole motif is positioned in an excellent complementarity with the narrow 
region of the ATP pocket. A result directed the steps to follow in the design of the opti-
mized structure (Figure 6). While retaining the 5-morpholinomethyl on the pyrazole-
benzimidazole motif, the benzamide portion was subjected to modifications. Keeping 
in mind the need to keep the molecular weight while introducing increased flexibility 
on the glycine region, the amide was converted to urea (20). This strategy was fruitful 
when comprehending that the urea analogue (20) exhibited reduced plasma protein 
binding while maintaining in vitro activity against Aurora kinases.
In the following step, the X-ray structure of (20) complexed with Aurora A was 
solved and iterated a similar binding mode to the hinge region. To resolve a twisted 
conformation of the phenyl plane in regard to pyrazole-benzimidazole portion 
of the molecule, a fully reduced cyclohexyl and difluorophenyl groups were also 
introduced (compound (20a) and (20b), respectively). Adsorption, disposition, 
metabolism, and excretion (ADME) considerations lead to proposing cyclopropyl 
derivative (21). As an alternative to introducing additional heterocyclic moiety, 
aiming at reducing the lipophilicity of (20a) for improving the ADME, the size 
of cyclohexyl ring was reduced to cyclopropyl analogue resulting in compound 
(21) that exhibits high enzyme and cellular potency still with reduced both the 
molecular weight (MW) and lipophilicity (log D7.4 = 2.1, MW = 381). Compound 
(21) demonstrated potent inhibition of HCT116 colony formation (IC50 = 12 nM), 
a clean CYP450 profile (IC50 > 10 μM for CYP3A4, 2D6, 1A2, 2C9, 2C19), accept-
able mouse plasma protein binding (81.5%), and good thermodynamic solubility 
(2.0 mg/mL at pH = 7.0 and 13 mg/mL at pH = 5.5).
Later, AT9283 (21) was shown to bind and potently inhibit a number of kinases 
including the Aurora kinases A and B (serine–threonine kinases that are known to 
play essential roles in mitotic checkpoint control during mitosis at IC50 ~ 3 nM), 
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Janus kinase 2 (JAK2) and JAK3 (1.2 and 1.1 nM, respectively), breakpoint cluster 
region-Abelson (BCR-Abl) T315I (4 nM), and mitogen-activated protein kinase 
kinase kinase 2 (MEKK2) with IC50 values of lower nanomolar (4.7–18 nM). This 
set of known kinases is known to play key roles in mitotic progress in cell cycle, 
induction of proliferation, evasion of apoptosis and tumor growth and thus con-
sidered vital targets to chemotherapeutic agents (see Table 1). Therefore, AT9283 
(21) is defined as multikinase (multitargeting) inhibitor [126].
AT-9283 inhibits effective proliferation of cancer cells both in vitro and in vivo 
with and its effect is enhanced by with other agents (see Table 2) [127]. Henceforth 
T9283 proceeded to clinical trials including in children with relapsed or refractory 
acute leukemia, imatinib-resistant BCR-Abl-positive leukemic cells, and patients 
with relapsed or refractory multiple myeloma. Accumulative results indicate a need 
for optimizing the pharmacological profile on the way to overcome faced challenges 
in clinical application of the compound [127, 128].
The activity in imatinib-resistant BCR-Abl chronic myelogeneous leukemia 
(CML) explained based on modeling which reiterated the assumption that AT-9283 
is bound to the kinase domain in the “folded conformation” which allows the 
needed interactions with the hinge region without a clash between the cyclopropyl 
group and the isoleucine residue in the T315I mutant. The results obtained in 
Figure 6. 
(a) Main steps in the identification and discovery of pyrazolebenzimidazole-based multitargeting agent 
AT9283 (21) using fragment-based identification starting from fragment (16). (b) The structure N-cyclopropyl-
N’-[3-[5-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl] urea [AT9283 (21a)]. The “folded 
conformation” of (21b). Dotted lines to indicate the hydrophobic interaction between the cyclopropyl and 
benzimidazole motifs [125].
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refractory CML suggest that AT-9283 can be efficient in Ph + acute lymphoblastic 
leukemia (Ph + ALL). It is the distinct binding mode that allows AT-9283 in similar 
manner to MK-0457 and PHA-739358 to exhibit potent activity against imatinib-
resistant T315I mutant [127, 129].
2.2.2 Binding mode of AT-9283 (21) to kinases
Currently, there exist 11 X-ray resolved crystallographic structures of AT-9283 
complexed with target proteins that are documented at the Protein Data Bank. They 
include aurora A, aurora B, mutant of aurora B, JAK2, and protein kinase A mutants 
as surrogate model for Aurora B. A closer look clarifies that in a similar manner to the 
binding of dovitinib, the benzene portion in benzimidazole fragment is pointing in 
an orientation toward the solvents’ exposed opening of the binding site. The pyrazole 
and urea fragments took part in multiple HBA and HBD interactions with the hinge 
region of the enzyme. The morpholine basic amine is oriented toward the solvent and 
enhanced significantly the solubility of the compound in physiological pH.
The crystal structure of compound (21) complexed with Aurora A is shown in 
Figure 7 [130]. The molecule is positioned at the ATP-binding site of the kinase. It is 
revealed the urea linker adopts a cis/trans configuration that results in the molecule 
having a “folded conformation.” This same conformation was also observed in the 
Inhibitory effect of AT9283 on tumor cell colony formation after 10–14 days treatment
Origin Cell line IC50 (nM) p53 status
Colon HCT116 13 +
HT-29 11 —
SW620 14 —
Ovarian A2780 7.7 +
Lung A549 12 +
Breast MCF7 20 +
Pancreatic MIA-Pa-Ca-2 7.8 —
+ indicates expression of wild-type p53; − indicates no expression of p53 or that p53 is nonfunctional [126].
Table 2. 
IC50s are the mean of two or more independent determinations.
Enzyme IC50 (nM)
Aurora A 52% I at 
3.0 nM
Aurora B 58% I at 
3.0 nM
JAK3 1.1
JAK2 1.2
Abl (T315I) 4
GSK3-β, FGFR2, VEGFR3 (Flt4), Mer, Ret, Rsk2, Rsk3, Tyk2, Yes 1–10
Abl(Q252H), DRAK1, FGFR1, FGFR1(V561 M), FGFR2(N549H), FGFR3, VEGFR1(Flt1), 
Flt-3, PDGFR-α(D842V), PDK1, PKCμ, Rsk4, SRC(T341 M), VEGFR2
10–30
Table 1. 
The inhibitory concentration 50% (IC50 of the “lead” (21)) [126].
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crystal structure of (21B) alone (Figure 8) and in DMSO. Such “folded conforma-
tion” was confirmed by NMR measurement. An NOE was observed between H3b/
H3b′ of the cyclopropyl ring and the H4 and H7 protons of the benzimidazole ring. 
This “folded conformation” was explained by the occurrence of additional stabiliza-
tion due to a hydrophobic interaction between these two groups.
The crystallographic structures of complexes both dovitinib-FGFR-1 and 
AT-9283 –Aurora A, revealed that there is a co-planarity between the benzimidazole 
and the quinolin-2-one of dovitinib, and pyrazole motif in AT-9283. A tautomeric 
rearrangement of the double bond induces a restriction on the rotation around the 
connection between the two fragments in each case (see Figure 8). This indicate the 
favorite binding to the less rotatable conformer (21B).
Recently AT-9283 was phase I/phase II trial of AT9283, a selective inhibitor of 
Aurora kinase in children with relapsed or refractory acute leukemia: challenges to 
run early phase clinical trials for children with leukemia [131–137].
2.3 α-Haloacetamidebenzimidazole derivatives as multitargeting agents
Employing virtual screening methods of PubChem database as a first step, 
selected support vector machine (SVM) virtual hits were evaluated by Lipinski’s 
Figure 7. 
(a) Cartoon representation of the crystallographic structure of complex pyrazol-4-yl urea AT9283 (21) 
complexed with JAK2 JH2 (PDB 5UT0); (b) the surface representation, with main interactions between 
(21) and the kinase domain, colored by atom type (red, oxygen; blue, nitrogen; yellow, sulfur; gray, carbon/
hydrogen). The donor-acceptor-donor motif is shown to interact with the hinge region, while morpholine 
substituent on C5 points toward the solution [130].
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rule of five. The compounds which passed Lipinski’s rule of five were subject to 
further and more refined screening by using molecular docking. This sequential 
refinement led to the identification of 2-aryl benzimidazole group of derivatives 
as multitarget “EGFR, VEGFR-2, and PDGFR” inhibitors [138]. A mechanistic 
study reported by Jiang and colleagues displayed that (22) exhibited low to 
moderate micromolar IC50 against nine established breast cancer cell lines that 
are known to have variable expressing EGFR and HER2 (MDA-MB-468, BT-549, 
MDA-MB-231, HCC1937, T-47D, BT-474, MDA-MB-453, ZR-75-1, MCF-7, and 
MCF-10 A). Using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay, (24 and 25) exerts moderate inhibitory effect on growth 
of panel of breast cancer cell lines (IC50 values of 2–9 μM) and was reported to be 
more potent than lapatinib against MDA-MB-468, BT-549, MDA-MB-231, ZR-75-
1, and MCF-7. A correlation was observed between the level of HER2 and EGFR 
amplification and expression and the sensitivity toward (22). IC50 = 3.58 μM 
against BT-474 (high expression of HER2), whereas against MDA-MB-453 (lower 
levels of HER2 expression) IC50 = 4.91 μM. The activity against lower EGFR 
and HER2 expressing cell lines (ZR-75-1 and MCF-7), IC50 = 1.81–2.99 μM was 
explained by the assumption that (22) is able to act via other targets of EGFR and 
HER2 [139].
Docking the compounds into kinase domains revealed that (22) occupies 
the ATP-binding site of EGFR (PDB: 2J6M). The compound was able to form 
a hydrogen bond with amino acid MET 793 (N–H⋯O:2.485 Å), claimed to be 
an important binding site of EGFR. The difference in the activity between the 
two compounds against VEGFR2 was explained by the difference in hydrogen 
bonding using docking into VEGFR-2 kinase. It was shown that (22) formed 
two hydrogen bonds with amino acids CYS917 (N–H⋯Cl:2.484 Å) and ASP1044 
(N–H⋯O:2.429 Å), whereas compound (23) formed only one hydrogen bond with 
ASP1044 (N–H⋯O:2.419 Å) [140].
The authors concluded that electron-withdrawing substituent residing at 2-aryl 
ring together with shorter aliphatic chain contributed to the cytotoxic potency and 
to the induction of apoptosis by such group of compounds in HepG-2 cell lines. 
Though reported as multitargeting agent, the activity of 2-chloro-N-(2-p-tolyl-
1H-benzo[d]imidazol-5-yl)acetamide (22) exhibiting most potency could not be 
explained explicitly by docking alone. (22) encompasses a reactive alphahaloacet-
amide (see Figure 9) that is vulnerable to nucleophilic substitution by biological 
Figure 8. 
Tautomeric rearrangement of multitarget inhibitors (1) and (21). (a) benzimidazole quinolin-2-one 
heterocyclic, and (b) benzimidazole pyrazole derivatives.
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nucleophiles like thiols (-SH). Thus, a study to explore the formation of irreversible 
adducts with cellular proteins like kinases is recommended and hoped to uncover 
the principal mechanism of its wide action.
2.4  2-Anilino-4-(benzimidazol-2-yl)pyrimidines: a multikinase inhibitor 
scaffold
Anilinopyrimidines (Figure 10) displays a wide range of bioactivities. Asymmetric 
2-anilinopyrimidines bearing 3-aminopropamides exhibit activity against epidermal 
growth factor receptor EGFR) [141]. 2-anilinopyrimidine derivatives bearing 4-piper-
idino substituents exhibited improved and selective activity against triple-negative 
breast cancer cell line MDA-MB-468 believed to be due to EGFR inhibition. Decorating 
the pyrimidine nucleus with different substituents at position 4 endowed the final 
derivatives (4-substituted-2-anilinopyrimidine) with activity as well as selective 
toward corticotropin-releasing factor (CRF) antagonists [142]. Having the anilino 
fragment at 2- together with thiazolyl at 4- of the pyrimidine core was reported to 
exert antagonistic effect of cyclin-dependent kinase-2 (CKD2) [143], and improved 
inhibitory activity toward CDK9 and (CDK2) [143–145].
Bis-anilinopyrimidine was reported as potent and selective PAK1 inhibi-
tor and as highly selective group I p21-activated kinase (PAK1) inhibitor [146]. 
Additionally, N-phenyl-N′-[4-(pyrimidin-4-ylamino)phenyl] urea derivatives (see 
(27) at Figure 10) exhibit selective inhibition to class III receptor tyrosine kinase 
subfamily [147]. Other symmetric 4,6-dianilinopyrimidines induce selective EGFR 
inhibitions [148].
Notably, introducing the benzimidazolyl moiety at position 4 of the 2- 
anilinopyrimidine core to produce 2-anilino-4-(benzimidazol-2-yl)-pyrimidines 
renders such group of compounds’ activity against a wider range of kinases (see 
Figure 10).
Renate Determann et al. reported the synthesis and in vitro activity of a small library 
of compounds that are based on the 2-anilino-4-(benzimidazol-2-yl)-pyrimidine 
scaffold (Figure 10, (30)) [142]. The most potent derivative exhibited antiproliferative 
activity for several cancer cell lines of the NCI panel in submicromolar concentrations. 
SAR study was concluded in indicating a basic correlation with the anilinopyrimidine 
fragment and the substitution pattern at the aniline moiety. It is worth mentioning that 
2-anilinopyrimidine fragment (Figure 10, (30)) is found in a range of kinase inhibitors.
Figure 9. 
α-Haloacetamidebenzimidazole derivatives as multitargeting agents. 2-chloro-N-(2-p-tolyl-1H-benzo[d]
imidazol-5-yl)acetamide (21), a novel 2-arylbenzimidazole derivative exhibited remarkable activity toward 
breast cancer. In a study reported by Jiang et al. (22 and 23) were virtually identified as multikinase EGFR and 
VEGFR inhibitor while (22) was identified as EGFR inhibitor and (23) as PDGFR inhibitor [140, 142].
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Based on high-throughput screening method radiometric protein kinase assay 
(33PanQinase® Activity Assay) [149], 11 recombinant cancer-related protein kinases 
(AKT1, ARK5, Aurora B, AXL, FAK, IGF1-R, MET, PLK1, PRK1, SRC, VEGF-R2) 
were screened by a library of compounds. Interestingly, four kinases (Aurora B, FAK, 
PLK1, and VEGF-R2) proved to be of particular sensitivity to the tested compounds 
(Table 3). This group of four kinases is involved in oncogenesis and maintenance of 
vital processes of cancer. Thus it is believed that their concerted inhibition could be 
useful in the treatment of various malignancies. It is worth noting the infectivity of 
most of tested compounds, including the active ones against AKT1 (shown in Table 3).
2.4.1 2-Anilino-4-(benzimidazol-2-yl)pyrimidine-target interactions
Though the authors did not report a prudent SAR, however, docking compound 
(33) to ATP-binding pocket of PLK1 (PDB 2OWB) helped rationalize the initial 
observations [142]. One main reflection highlighted the positioning of the ani-
linopyrimidine fragment in the hinge region, forming a pair of hydrogen bonds 
to Cys133. Methoxy (CH3O-) group at the position 2 of the aniline moiety forms a 
Figure 10. 
Development of multitargeting 2-anilino-4-(benzimidazol-2-yl)-pyrimidine scaffold (30) starting from 
hinge binding compound 1,3-dimethyl-7-(1-methyl-1H-benzimidazol-2-yl)pyrido[2,3-d]pyrimidine-
2,4(1H,3H)-dione (31). 2-anilino-4-(benzimidazol-2-yl)-pyrimidine derivatives 2-methoxy-5- 
{[4-(1-methyl-1H-benzimidazol-2-yl)pyrimidin-2-yl]amino}phenol (33) most potent compound and 
2-anilino-4-(benzimidazol-2-yl)-pyrimidine derivatives 2-hydroxy-5-{[4-(1-methyl-1H-benzimidazol-2-yl)
pyrimidin-2-yl]amino}phenol (32))), 4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-ylamine (35), and 2-anilino-
4-(thiazol-5-yl)pyrimidine (29).
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hydrogen bonding with the guanidine of Arg136 residing at the opening of the PLK1 
ATP-binding pocket. The inactivity of derivatives with substituents bulkier than 
methoxy group (CH3O-) was explained partially by the clash with Leu59 and Arg136 
at the pocket entrance indicating limited tolerance to variation at this region.
2.5 Benzimidazolylamidines as multitargeting agents
Silvana Raić-Malića and colleagues reported the synthesis of a group of benz-
imidazole amidine derivatives [150]. Specifically, compound (Figure 11, (36)) 
abrogated the activity of several protein enzymes including tissue transglutaminase 
(TGM2) and kinases like CDK9, sphingosine kinase 1(SK1), and p38 mitogen-
activated protein kinase (p38 MAPK), whereas compound (37) did not have 
profound effect on CDK9 and TGM2 but showed moderate downregulation of SK1 
and significant reduction in p38 MAPK.
A small library comprising 27 compounds was screened for the potency. 
Two of them, p-chlorophenyl-substituted 1,2,3-triazolyl derivatives of amidine 
N-isopropyl amidine (36) and imidazoline amidine (37), exhibited remarkable 
antiproliferative activities with IC50 of 0.05 and 0.06 μM in non-small cell lung 
cancer cells A54 and was defined as multitarget inhibitors.
In their endeavor to look for potent inhibitors for treatment of non-small cell 
lung cancer, Silvana Raić-Malić and her team developed a group of benzimidazole 
amidine derivative that showed an inhibitory effect on several key players in cancer 
AKT1 Aurora 
B
FAK PLK1 VEGF-R2
>100 7 ± 2.3 10.4 ± 2.7 6.0 ± 0.1 7.5 ± 2.0
>100 6.0 ± 0.2 3.4 ± 0.8 1.2 ± 0.2 7.2 ± 0.3
>100 >100 92 >100 85
Sorafenib >10 1.8 >10 >10 0.022
Sunitinib >10 1.5 1.6 >10 0.070
Compound (33) exhibited activities that range between IC50 = 1.2 and 7.2 μM [142].
Table 3. 
Protein kinase inhibition by (32 and 33) compared pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (39) to 
standard multitargeting FDA-approved agents sorafenib and sunitinib.
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proliferation [150]. A recent study reported that synthesis of amidino 2-substituted 
benzimidazoles linked to 1,4-disubstituted 1,2,3-triazoles by applying microwave 
and ultrasound irradiation in click reaction and subsequent condensation of thus 
obtained 4-(1,2,3-triazol-1-yl)benzaldehyde with o-phenylenediamines. The study 
concluded the improved cytotoxic effect (within the nanomolar range; IC50 of 50 
and 60 nM) against hepatocellular carcinoma cells. A follow-up study affirms the 
conclusion that when benzimidazole is conjugated to 1,2,3-triazole moiety, the 
hybrid exerts potent and selective antiproliferative effect against a panel of cell lines 
[non-small cell lung cancer (A549), ductal pancreatic adenocarcinoma (CFPAC-1), 
cervical carcinoma (HeLa), and metastatic colorectal adenocarcinoma (SW620) as 
well as on normal human lung fibroblasts (WI38)] with 5-fluorouracil (5FU) as a 
positive control. Two hits (36) and (37) (Figure 11a) demonstrated a potent activity 
at nM range (IC50 of 50 and 60 nM) against non-small cell lung cancer (A549). 
Interestingly, benzyl-substituted 1,2,3-triazolyl analogue of imidazoline (36) 
exhibited a remarkable and selective activity (IC50 = 0.07 μM) on A549 cell line. A 
mechanistic study performed on A549 cell line using Western blotting reinforced 
the belief that nature of aromatic substituent of 1-(1,2,3-triazolyl) and amidino 
moiety at C-5 position of benzimidazole ring is critical to the cytostatic activity of 
this group of compounds. In silico analysis supported the conception that (36) is 
bound slightly better than (37) to ATP-binding site of p38 MAPK, which correlates 
with observed decrement in the expression level of phospho-p38 MAPK displayed 
by (36). The importance of triazole was referred to its ability to form one H-bond 
with Met109 in the hinge region. Aminobenzimidazole group forms a number of 
HB with polar amino acids Glu71, Hid148, and Asp168 in the linker region. Phenyl 
moieties found on the hybrid both are placed in the hydrophobic environment. The 
phenyl connected to the triazole is assumed to participate in a π-π stacking with 
Phe169 (see Figure 11). The study reported (36) as a multitarget inhibitor since it 
abrogated the activity of several protein kinases including TGM2, CDK9, SK1, and 
p38 MAPK.
Figure 11. 
(a) Hit compounds prepared and screened for multitarget action 2-(4-((1-Benzyl-1H-1,2,3-triazol-
4-yl)methoxy)phenyl)-5-(4,5-dihydro-1H-imidazol-2-yl)-1H-benzo[d]imidazole hydrochloride 
(36),2-(4-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-N-isopropyl-1H-benzo[d]imidazole-
6-carboximidamide (37); (b) summary of structure–activity relationship of benzimidazolylamidines [150].
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3. Conclusion
3.1 Multitargeting and polypharmacology
According to the definition of Richard Morphy, the multitarget drugs are 
defined as “compounds that are designed to modulate multiple targets of relevance 
to a disease, with the overall goal of enhancing efficacy and/or improving safety” 
(Morphy, Rankovic, 2005) [151].
Modulating the function of numerous biological molecules is a well-
established pharmacological approach in medicine practice. Paracetamol, a 
traditional therapeutic used worldwide, is believed to induce its effects via action 
on multiple targets. Several psychoactive, serotonergic, cholinergic, and adren-
ergic agonists or antagonists exercise their actions on a wider range of singular 
biomolecular target.
Apart from the alphachloroacetamidobenimidzoles (22), the groups of 
compounds reported so far in the literature as multitarget agents act in most 
cases on receptor tyrosine kinases (RTKs) as competitive ATP inhibitors. Those 
by virtue occupy the vicinity of ATP with the heteroaromatic system interac-
tively buried in the purine portion pocket and interact with the hinge region of 
the kinase domain. The thiol (-SH)- π and the stacking π-π together with the 
hydrophobic interaction with the floor and the ceiling of the purine-binding 
regions are believed to do the required binding adjustment as kinase inhibitors. 
Crystallographic structure of dovitinib human FGFR1 revealed the occupancy of 
the purine-binding regions (part of the ATP-binding site) with the quinolinone-
benzimidazole fragment, while the N-methylpiperazine attached to C5’ at the 
phenyl part of the benzimidazole is pointing toward the opening and is exposed 
to the solution. Thus, it seems that benzimidazole portion is not interacting 
directly with the hinge region of the enzyme. Similar binding is noticed with 
AT9382. The pyrazolylbenzimidazole and the benzamide motif take part in HBD-
HBA bridging with the hinge of the kinase domain.
In the case of 2-anilino-4-(benzimidazole-2-yl)pyrimidine, the benzimidazole por-
tion looks immersed deep in the purine-binding regions of the ATP-binding site partici-
pating in direct interactions via hydrogen bonding and hydrophobic interactions, while 
the hydroxymethoxyaniline portion points towards the solvent exposed area.
3.2 Lessons learnt
3.2.1 Discovery methods
Despite the imbedded potential, the multitarget activity of the reported 
benzimidazole-based scaffolds was identified serendipitously. In other words, none 
of the benzimidazole anticancer multitargeting agents seem to be identified in 
unforeseen manner, and in many ways they emerge with no intention to be designed 
initially. While adhering to the development of selective and specific agents, results 
accumulated afterword revealed multitarget action. For example, 3-benzimidazol-
2-ylhydroquinolin-2-one scaffold [benzimidazolylquinolinone (Figure 4, (12)] 
was identified using high-throughput screening (HTS). AT9283 (Figure 6, (21)) 
was identified following fragment-based structural approach with the initial aim to 
develop an Aurora selective inhibitor, and later it was reported to act as multitarget-
ing agent.
It is hoped that the identification, discovery, and optimization of benzimidazole-
based multitargeting anticancer agent will benefit from the “big data era” fueled by 
data available from public repositories.
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3.2.2 Shift in the paradigm
Multitargeting can occur via three possible ways: acting on the same target, on 
different targets of the same pathway, or on different targets of different pathways. 
So far the benzimidazole derivatives that have been explored are reported to act as 
the third category “acting on different targets of different pathways.” The focus has 
been so far on the kinome-relevant signaling key player with dovitinib widening the 
landscape to non-kinase targets. Broadening “multitargeting” concept to identify 
novel inhibitors with potency against key targets outside the human kinome neces-
sitates treating complex diseases using “polypharmacology” gains special interest in 
resistant mutated spreadable cancers [151].
Despite the initial enthusiasm for the efficacy of molecular targeted therapeutics 
following the approval of imatinib, a small tyrosine kinase inhibitor targeting BCR-
Abl, in chronic myeloid leukemia (CML) and trastuzumab, a monoclonal antibody 
against HER2, for treatment of metastatic breast cancer, scientists and clinicians 
were challenged by recurrent relapse due to cancer patients who developed drug 
resistance. In the case of RTKi, resistance can emerge as a result of selection for 
mutant sin in the target that renders the binding site inaccessible, reduced influx 
accompanied by enhance efflux, shift in metabolism and excretion of the drug, and 
the activation of alternative signaling pathways. Thus, the rationale for targeting 
drugs is shifting. In the last two decades, the main effort was aimed at developing 
highly specific inhibitors acting on single target. Now, there is a general agreement 
that molecules interfering simultaneously with multiple RTKs might be more effec-
tive than single-target agents. With the recent approval by the FDA of sorafenib, 
regorafenib, sunitinib, lenvatinib, and axitinib-targeting VEGFR, PDGFR, FLT-3, 
and c-KIT—more attention is drawn to broad-spectrum anticancer properties 
multikinase targeting drugs. Thus it is anticipated that more multitargeting agents 
will be getting into clinical trials and making their way to clinical application. It 
is hoped that identification, discovery, and optimization of benzimidazole-based 
multitargeting agents will benefit from the “big data era” fueled by the availability 
of big data, advances in technology, and artificial intelligence.
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Acronyms and abbreviations
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
 tetrazolium bromide
PRK1 actin-regulating kinase
MEK1 activated protein kinase
AML acute myeloid leukemia
ADME adsorption, disposition, metabolism, excretion
ARK5 AMPK-related kinase 5
ALK anaplastic lymphoma kinase
ALP   alkaline phosphatase
AXL   “anexelekto” receptor tyrosine kinase
BCR-Abl   breakpoint cluster region-Abelson kinase
CK2   casein kinase 2
CXCR3   chemokine receptor
CML   chronic myelogeneous leukemia
DHODH   dihydroorotate dehydrogenase
D2R   dopamine receptor 2
FGFR-1/FGFR-2/FGFR-3 fibroblast growth factor receptors 1, 2, 3
FAK   focal adhesion kinase
IC50   half maximal inhibitory concentration
HGF or MET   hepatocyte growth factor
H4H   histamine receptors 4
HDAC2   histone deacetylase 2
MDA-MB-468   human breast carcinoma cell lines
HER2   human epidermal growth factor receptor 2
HB   hydrogen bind
HBD   hydrogen bond donor
HBA   hydrogen bond acceptor
5-HTR   hydroxytryptamine receptors
CDK   inhibition of cyclin-dependent kinases
IGF-1R   insulin-like growth factor 1 receptor
ITK   interleukin 2-inducible T-cell kinase
JAK-1/JAK-2/JAK-3  Janus kinase-1/2/3
LE   ligand efficiency
Lck   lymphocyte tyrosine kinase
MEKK2   mitogen-activated protein kinase kinase kinase 2
nM   nanomolar
μM   micromolar
PAK1   p21-activated kinase
p38 MAPK   p38 mitogen-activated protein kinase
Ph + ALL   Ph + acute lymphoblastic leukemia
PI3K   phosphatidylinositol 3-kinase
PDGFR-α/β   platelet-derived growth factor receptor-α/β
PLK-1   polo-like kinase 1
PARP-1   poly(ADP-ribose)polymerase-1
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ATP   adenosine triphosphate
PDB   Protein Data Bank
AKT1   RAC-alpha serine/threonine-protein kinase
PTKs   protein tyrosine kinase
PTP   protein tyrosine phosphatases
c-KIT   stem cell factor receptor
FLT3   FMS-like tyrosine kinase 3
FLT3-ITD   FMS-like tyrosine kinase 3 internal tandem   
  duplication
SAR   structure–activity relationship
SVM   support vector machines
ATR   telangiectasia and Rad3-related protein kinase
TOPO1/TOPO2   topoisomerase 1/2
TKRs   tyrosine kinase receptors
VEGFR-1/VEGFR-2/VEGFR-3 vascular endothelial growth factor receptor-1, 2, 3
SRC   v-src sarcoma (Schmidt-Ruppin A-2) viral onco  
  gene homolog (avian)
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